<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391662</url>
  </required_header>
  <id_info>
    <org_study_id>BIBABRAX</org_study_id>
    <secondary_id>2014-003596-27</secondary_id>
    <nct_id>NCT02391662</nct_id>
  </id_info>
  <brief_title>A Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación de Oncología Médica del Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación de Oncología Médica del Hospital de Cruces</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer
      is 1:3. Although many clinical trials include elderly patients, no results for this subgroup
      of patients are available. Since there is no specific recommendations for treatment of
      elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment
      of choice for these patients.

      Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and
      targeted agents to gemcitabine has almost invariably provided no significant survival
      improvement.

      Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic
      cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in
      overall survival, but due to in this clinical trial was included patients between 27 and 88
      years, it is considered necessary to conduct a specific study for patients over 70 years.

      The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel
      associated with gemcitabine can be extended to elderly patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment through 3-months deterioration free rate</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The general deterioration of the patient is assessed with the EORTC-QLQ-C30 scale. t will be considered definitive deterioration a decrease of at least 10 points from baseline. We will evaluate the rate of patients free of definitive deterioration at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety profile of gemcitabine and nab-paclitaxel, measured by Number of events per patient according to NCI-CTC-AE criteria</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of events per patient according to NCI-CTC-AE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Time from patient inclusion to disease progression according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time from patient inclusion to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective radiographic response (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Response rate will be evaluated according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19.9 biomarker response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>CA 19.9 biomarker response will be considered a decrease of at least 50% compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Carcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1, 8 &amp; 15 in a 28 days cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1000 weeks 1,2,3/4</intervention_name>
    <description>Gemcitabine 1000 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically-confirmed pancreatic adenocarcinoma

          -  Stage IV disease (metastatic only)

          -  No prior systemic therapy for their diagnosis (except in adjuvant setting &gt; six
             months previously)

          -  ECOG performance status of 0-1

          -  Age &gt;=70 years.

          -  Evidence of either or both of the following:

               -  RECIST-defined measurable disease (lesions that can be accurately measured in at
                  least one dimension with the longest diameter &gt;= 20mm using conventional
                  techniques or &gt;= 10 mm with spiral CT scan)

               -  An elevated serum CA19-9 at baseline ( &gt;= 2X ULN)

          -  Female patients must be either surgically sterile or postmenopausal.

          -  Male patients must be surgically sterile or must agree to use a condom during sex
             with women who may become pregnant while receiving the study drug and for 6 months
             after receiving the last dose.

          -  Adequate bone marrow function:

               -  ANC &gt;= 1500/uL

               -  platelet count &gt;= 100,000/uL

               -  hemoglobin &gt;= 9.0 g/dL

          -  Adequate hepatic function:

               -  Total bilirubin &lt;= 1.5 X ULN

               -  AST (SGOT) &lt;= 2.5 X ULN

               -  ALT (SGPT) &lt;= 2.5 X ULN

          -  Adequate renal function as determined by either:

               -  Serum creatinine &lt;= 1.5 X ULN

               -  Calculated or measured creatinine clearance &gt;= 40 mL/min (for calculated
                  creatinine clearance, Cockroft-Gault equation will be used).

          -  Ability to understand the nature of this study protocol and give written informed
             consent

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          -  Any prior systemic or investigational therapy for metastatic pancreatic cancer.

          -  Inability to comply with study and/or follow-up procedures.

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition
             that, in the opinion of the investigator, renders the subject at high risk from
             treatment complications or might affect the interpretation of the results of the
             study.

          -  Presence of central nervous system or brain metastases.

          -  Life expectancy &lt; 12 weeks.

          -  Pregnancy (positive pregnancy test) or lactation.

          -  Prior malignancy except for adequately treated basal cell skin cancer, in situ
             cervical cancer, adequately treated Stage I or II cancer from which the patient is
             currently in complete remission, or any other form of cancer from which the patient
             has been disease-free for 5 years.

          -  Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic
             coronary artery disease and cardiac arrhythmias not well controlled with medication)
             or myocardial infarction within the last 12 months.

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome.

          -  Known, existing uncontrolled coagulopathy.

          -  Pre-existing sensory neuropathy &gt; grade 1.

          -  Major surgery within 4 weeks of the start of study treatment, without complete
             recovery.

          -  Concurrent/pre-existing use of anticoagulant treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo López Vivanco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Cruces</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan L Sanz</last_name>
    <phone>+34918166804</phone>
    <phone_ext>103</phone_ext>
    <email>juanluis.sanz@apices.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana M Moreno</last_name>
    <phone>+34918166804</phone>
    <phone_ext>100</phone_ext>
    <email>ana.moreno@apices.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Vicente, MD</last_name>
      <email>pvicente@fhag.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalari de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08240</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Casado, MD</last_name>
      <email>ecasado@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Gipuzkoa</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo López Vivanco, MD</last_name>
      <email>GUILLERMO.LOPEZVIVANCO@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica Jorge, MD</last_name>
      <email>monica.jorge.fernandez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>San Cristóbal de La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Llanos, MD</last_name>
      <email>martallanosmunoz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertomeu Massuti, MD</last_name>
      <email>bmassutis@seom.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Delgado, MD</last_name>
      <email>pvicente@fhag.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos García Girón, MD</last_name>
      <email>cgarciag@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene González Cebrián, MD</last_name>
      <email>oncojaen@fibao.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. Hospitalario Universitario Insularmaterno-Infantil</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen García Piernavieja, MD</last_name>
      <email>carmengarciapj@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Quintero, MD</last_name>
      <email>gquinteroaldana@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Mondéjar, MD</last_name>
      <email>rmondejars@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Feliú, MD</last_name>
      <email>jaimefeliu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico González, MD</last_name>
      <email>ensayosoncologia.mad@quiron.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Fernández Montes, MD</last_name>
      <email>afm1003@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Albero</last_name>
      <email>casablanca37@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>March 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Pancreatic Adenocarcinoma</keyword>
  <keyword>Elderly</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
